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The matrix (MA) domain of the HIV-1 structural precursor Gag (PrGag) protein targets PrGag proteins to membrane assembly sites, and
facilitates incorporation of envelope proteins into virions. To evaluate the specific requirements for the MA membrane-binding domain (MBD) in
HIV-1 assembly and replication, we examined viruses in which MAwas replaced by alternative MBDs. Results demonstrated that the pleckstrin
homology domains of AKT protein kinase and phospholipase C δ1 efficiently directed the assembly and release of virus-like particles (VLPs)
from cells expressing chimeric proteins. VLP assembly and release also were mediated in a phorbol ester-dependent fashion by the cysteine-rich
binding domain of phosphokinase Cγ. Although alternative MBDs promoted VLP assembly and release, the viruses were not infectious. Notably,
PrGag processing was reduced, while cleavage of GagPol precursors resulted in the accumulation of Pol-derived intermediates within virions. Our
results indicate that the HIV-1 assembly machinery is flexible with regard to its means of membrane association, but that alternative MBDs can
interfere with the elaboration of infectious virus cores.
© 2007 Elsevier Inc. All rights reserved.Keywords: Assembly; Gag; HIV; Matrix; Membrane; RetrovirusIntroduction
The matrix (MA) domain of the HIV-1 precursor Gag
(PrGag) protein serves at least two assembly functions: it targets
PrGag proteins to membrane assembly sites, and it facilitates the
incorporation of the SU/TM envelope (Env) glycoprotein
complex into virions (Mammano et al., 1995; Ono and Freed,
1999, 2004; Ono et al., 1997, 2000a, b; Pal et al., 1990; Wang
and Barklis, 1993; Wang et al., 1993; Wyma et al., 2000; Yu
et al., 1992; Zhou et al., 1994). In terms of membrane targeting,
there is some debate as to the pathways by which PrGag
proteins travel to arrive at productive assembly sites. One
possible itinerary involves PrGag association with intracellular
membranes such as multivesicular bodies (MVBs), followed by
vesicular delivery to the plasma membrane (PM) (Bryant and
Ratner, 1990; Davis et al., 2006; Dorfman et al., 1994; Freed
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or with the delivery of PrGag proteins on vesicle cytoplasmic
faces to final PM assembly sites (Jones et al., 1990). An
alternative travel plan for PrGag proteins is a direct route to the
PM (Jouvenet et al., 2006; Ono and Freed, 2004; Saad et al.,
2006). In this case, the accumulation of PrGag proteins on
intracellular membranes could be viewed as representing dead
end assembly products, or internalized PM components, enroute
to lysosomal degradation. An intermediate hypothesis is that
direct PM targeting and vesicle-mediated transport both can
yield infectious virions, depending on the cell type or context
(Ono and Freed, 2004).
A number of biochemical and genetic studies have identified
different features of HIV-1 MA that influence PrGag localiza-
tion, membrane binding, and assembly (Bryant and Ratner,
1990; Facke et al., 1993; Lindwasser and Resh, 2001, 2002;
Murray et al., 2005; Ono and Freed, 1999; Ono et al., 2000a,
2004; Pal et al., 1990; Saad et al., 2006; Tang et al., 2004; Wang
and Barklis, 1993; Wang et al., 1993; Wang et al., 1994). With
regard to localization, the amino-terminal α-helical segment of
HIV-1MA recently was shown to associate with the δ subunit of
the AP-3, and this interaction appears important for PrGagMVB
localization (Dong et al., 2005). Evidence also has shown that
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with the μ subunit of the clathrin-associated adapter complex
AP-2, but that PrGag processing eliminates this interaction
(Batonick et al., 2005). Consistent with the role of AP-2 in PM
cargo internalization, inhibition of MA–AP-2 binding increased
virus particle release from cells (Batonick et al., 2005). In
addition to adapter protein binding, HIV-1 MA also contributes
to the binding of the cellular motor protein KIF-4, an association
that plausibly regulates the distribution of PrGag (Tang et al.,
1999). Recent investigations also demonstrated that MA resi-
dues 5–16 are necessary for PrGag binding to the tail interacting
protein TIP47, which mediates a functional association of MA
with Env (Lopez-Verges et al., 2006).
While the above protein–protein interactions affect virus
infectivity and PrGag localization, membrane binding is
impacted greatly through MA–lipid interactions. The MA
N-terminus is critical in this process. Like other mammalian
retrovirus matrix proteins, HIV-1 MA is myristoylated at its
N-terminus, and myristoylation is essential for efficient
membrane binding, virus assembly, and infectivity (Bryant
and Ratner, 1990; Pal et al., 1990; Saad et al., 2006; Tang et al.,
2004; Wang and Barklis, 1993). Studies support a myristoyl
switch model for MA membrane association, in which the
myristate group of PrGag inserts into membranes to promote
binding, but that this fatty acid is retracted on proteolytic
processing of PrGag, conferring a reduced membrane affinity
for mature MA proteins (Hermida-Matsumato and Resh, 1999;
Paillart and Gottlinger, 1999; Spearman et al., 1997; Tang et al.,
2004). Although the MA myristate is necessary for tight
PrGag–membrane binding, it is not the only contributor.
Analysis indicates that basic amino acids between residues 15
and 40 facilitate electrostatic interactions with negatively
charged phospholipid headgroups on the cytoplasmic faces of
membranes (Murray et al., 2005; Ono and Freed, 1999; Zhou
et al., 1994). However, HIV-1 MA also specifically associates
with phosphatidylinositol (4,5) bisphosphate [PI(4,5)P2] (Ono
et al., 2004; Saad et al., 2006). In particular, the PI(4,5)P2
headgroup and 2′-acyl chain are accommodated by a cleft in the
protein, and binding results both in the membrane-anchoring by
the PI(4,5)P2 2′-acyl chain, and in triggering the exposure of the
MA myristate (Saad et al., 2006). Given the affinity of MA for
PI(4,5)P2, it is plausible that PI(4,5)P2 helps direct PrGag to
cholesterol- and dihydrosphingomyelin-rich membrane
domains, where HIV-1 assembly appears to occur (Booth et
al., 2006; Brugger et al., 2006; Holm et al., 2003; Nguyen and
Hildreth, 2000; Ono and Freed, 2001).
Despite the many documented roles for HIV-1 MA, it is not
absolutely required for virus infectivity. We originally demon-
strated the infectivity of a 106 residue MA deletion mutant that
retained only the myristoylation signal and matrix-capsid (CA)
cleavage site (Wang et al., 1993), an observation that sub-
sequently was confirmed by others (Reil et al., 1998). In such
cases, infection required either an Env protein pseudotype, or
truncation of the HIV-1 Env cytoplasmic tail (Reil et al., 1998;
Wang et al., 1993). These deletion mutant results imply that
wild type (wt) HIV-1 Env function requires MA, but that intact
MA is not strictly required for viral replication.The studies above suggest that any membrane targeting and
anchor protein might suffice for directing the assembly of
infectious HIV-1 particles. However, a caveat to this interpre-
tation is that the aforementioned MA deletion proteins retained
myristoylation signals (Reil et al., 1998; Wang et al., 1993).
Thus, a narrower hypothesis is that membrane interactions
mediated by myristate are compatible with HIV-1 assembly and
infectivity, while other membrane interaction motifs may or
may not serve this role. To analyze this hypothesis further, we
have examined HIV-1 MA protein substitution variants for their
abilities to replace MA. For our investigations, we chose three
alternative membrane-binding domains (MBDs). One of these
was the AKT protein kinase pleckstrin homology (PH) domain,
which preferentially binds to 3′ phosphatidyl inositol (PI) lipids
such as phosphatidyl inositol (3,4) bisphosphate [PI(3,4)P2],
and the PM-enriched phosphatidyl inositol (3,4,5) trisphosphate
[PI(3,4,5)P3] (Haugh et al., 2000; Hurley and Meyer, 2001;
Lemmon, 2003; Marshall et al., 2001). The second MBD was
the PH of phospholipase C δ1 (PLC), which has affinity for PM-
localized PI(4,5)P2 (Hurley and Meyer, 2001; Lemmon, 2003;
Stauffer et al., 1998). Finally, we examined the phosphokinase
Cγ cysteine-rich C1a plus C1b binding domain (CBD), which
binds PM diacylglycerol (DAG), and can be activated by phor-
bol esters to move from intracellular stores to the PM (Colon-
Gonzalez and Kazanietz, 2006; Edwards and Newton, 1997;
Hurley and Meyer, 2001; Oancea and Meyer, 1998; Oancea
et al., 1998). When the AKTPH, PLCPH, and PKCCBD were
employed as substitutes for MA, we found that the two PH
domains readily directed PrGag proteins to assemble and re-
lease virus-like particles (VLPs) from cells, while PKCCBD-
Gag proteins could be induced to release VLPs with phorbol
esters. However, the VLPs that used alternative MBDs were
non-infectious, either with HIV-1 Env, or with other Env pseu-
dotypes. Assembly-competent but non-infectious AKTPH- and
PLCPH-derived VLPs showed nearly normal viral RNA
(vRNA), Env protein pseudotype, and entry levels, but had
reduced reverse transcriptase (RT) activities, and were defective
for DNA synthesis in target cells. Moreover, all MA substitution
viruses showedmoderate protease (PR) processing defects of the
PrGag proteins. Additionally, precursor GagPol (PrGagPol)
processing resulted in the accumulation of Pol-derived inter-
mediates in virions, suggesting unexpected MBD effects on the
regulation of later Pol protein cleavage steps. Our results
indicate that while the membrane targeting and assembly
functions of HIV-1 MA can be replaced, alternative MBDs
compromise virus infectivity by perturbation of virus core
structure and function.
Results
Particle release directed by alternative membrane-binding
domains
To analyze whether the AKTPH, PLCPH, or PKCCBD
membrane-binding domain could replace HIV-1MA in directing
the assembly and budding of HIV virus-like particles, we
initially examined VLPs released from cells transfected with the
Fig. 1. Recombinant DNA constructs. Recombinant DNA constructs. All
recombinant constructs express variants of the HIV-1 HXB2 gag gene that
ordinarily is translated into the precursor Gag (PrGag) protein. Wild type (wt)
versions of the HIV-1 gag gene, expressed in the presence of pol gene products,
were produced from the previously described HIVgpt construct (Scholz et al.,
2005; Wang and Barklis, 1993; Wang et al., 1993). In control experiments, HIV-
1 protease-minus (PR−) proteins were expressed from the previously described
HIVgpt2498T plasmid (Wang and Barklis, 1993; Zhang and Barklis, 1997).
GFP-AKTPH-Gag, GFP-PLCPH-Gag, and PKCCBD-GFP-Gag generate PR−
Gag fusion proteins in which the HIV MA domain has been replaced with the
green fluorescence protein (GFP) plus the AKT protein kinase pleckstrin
homology (PH) domain (Hermida-Matsumato and Resh, 1999; Marshall et al.,
2001), the phospholipase C δ1 (PLC) PH domain (Stauffer et al., 1998), or the
cysteine-rich membrane-binding domain (CBD) from phosphokinase Cγ (PKC;
Oancea and Meyer, 1998; Oancea et al., 1998). The depicted HIVgpt constructs
are variants of the wt HIVgpt plasmid (Page et al., 1990; Wang and Barklis,
1993; Wang et al., 1993), and express proteins in the presence of HIV-1 pol gene
products. HIVgpt-MAGFP carries the GFP coding region in-frame as an insert
near the C-terminal end of MA. HIVgpt-AKTPH, HIVgpt-PLCPH, and HIVgpt-
PKCCBD derive from a myristoylation-minus HIVgpt construct (Wang and
Barklis, 1993), and replace matrix residues downstream from codon 16 and
upstream from the MA/CA juncture region (codon 120) with the AKTPH,
PLCPH, or PKCCBD membrane-binding domains. Juncture sequences and
construct details are provided in the Materials and methods.
Fig. 2. Release of virus-like particles. Release of virus-like particles. Cells were
transfected with wt HIVgpt (wt HIV) or the indicated constructs and either
untreated or treated with 1 μM PMA or PDB. At 72 h post-transfection, cell and
VLP samples were collected, subjected to SDS-PAGE and anti-HIVCA
immunoblotting. Cellular PrGag and VLP PrGag plus CA levels were quan-
titated densitometrically, raw release levels ([VLP PrGag+CA]/[Cell PrGag])
were calculated and are shown, normalized to untreated wt HIVgpt release
levels. Results derive from one (wt HIV+PDB; PKCCBD-GFP-Gag+PDB),
two (wt HIV+PMA; HIVgpt-MAGFP), three (PCKCBD-GFP-Gag+PMA), or
four (GFP-AKTPH-Gag; GFP-PLCPH-Gag; PKCCBD-GFP-Gag) separate
experiments. Standard deviations are as shown.
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Gag, and PKCCBD-GFP-Gag. As illustrated in Fig. 1, these
plasmids express PrGag proteins from PR− constructs in which
the HIV-1 wild type (wt) Gag domains from CA through p6 were
linked to N-terminal modules composed of green fluorescence
protein (GFP) and MBD units. For controls in these studies, we
employed a wt HIV-1 Gag expression construct, HIVgpt
(McDermott et al., 1996; Page et al., 1990; Wang and Barklis,
1993;Wang et al., 1993, 1994; Zhang and Barklis, 1997), as well
as HIVgpt-MAGFP (Fig. 1), in which the GFP coding region has
been inserted near the C-terminus of MA, in a fashion similar to
the GFP-Gag construct described by Muller et al. (2004).
Consistent with previous results (McDermott et al., 1996;
Wang and Barklis, 1993; Wang et al., 1993; Zhang and Barklis,
1997), in transfected cells, the wt HIVgpt construct expressed
Gag proteins and efficiently assembled and released virus
particles. When cells transfected with the wt construct were
treated with the phorbol esters PMA or PDB, we did not observe
any noticeable changes on wt virus release levels (Fig. 2).
Relative to the wt construct, our HIVgpt-MAGFP construct
appeared to release slightly reduced Gag protein levels, whileresults with our matrix replacement constructs were varied
(Fig. 2). With the PH substitutions GFP-AKTPH-Gag and GFP-
PLCPH-Gag VLPs were assembled and released efficiently
(Fig. 2). In contrast, PKCCBD-GFP-Gag proteins failed to
release VLPs to media samples. However, because PKCCBD
binds DAG and is activated by phorbol esters (Colon-Gonzalez
and Kazanietz, 2006; Edwards and Newton, 1997; Hurley and
Meyer, 2001; Oancea and Meyer, 1998; Oancea et al., 1998),
we also tested whether phorbol myristate acetate (PMA) or
phorbol dibutyrate (PDB) could mobilize the release of
PKCCBD-GFP-Gag VLPs. Interestingly, while the phorbol
esters had no apparent effect on the release of wt HIV particles,
they clearly increased particle release directed by the PKCCBD
(Fig. 2).
To verify that GFP modules were retained on the full-length
PrGag proteins expressed by the matrix replacement constructs,
VLP samples were electrophoresced in parallel and then
immunoblotted for detection of either HIV-1 CA or GFP. Not
surprisingly, none of the wt HIV-1 bands detected with our CA
antibody was observed when the anti-GFP antibody was
employed whereas with matrix replacement VLPs, each of the
lowest mobility PrGag proteins visualized with anti-CA, also
was seen with anti-GFP, supporting the conclusion that these
represent the full-length PrGag proteins (data not shown). The
incorporation of GFP into the VLPs of GFP-AKTPH-Gag,
GFP-PLCPH-Gag, and PKCCBD-GFP-Gag permitted us to
monitor VLP formation via fluorescence microscopy, and as a
control, we took advantage of the availability of HIVgpt-
MAGFP particles. When subjected to fluorescence microscopy,
HIVgpt-MAGFP VLPs were observed as bright green spots
(data not shown), similar to the appearance of vpr-GFP-labeled
HIV-1 particles (Muthumani et al., 2000). Particles assembled
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imaged as green spots, while for PKCCBD-GFP-Gag, fluores-
cent VLP release required phorbol ester induction. These results
lend qualitative support to the results presented in Fig. 2.
Cellular localization of alternative Gag proteins
Where do matrix replacement Gag proteins accumulate
within cells? We addressed this question via microscopic
tracking of fluorescent proteins in transfected cells. With
HIVgpt-MAGFP, the fluorescent proteins were observed at cell
surfaces and perinuclear regions, as well as in a heteroge-
neously staining pattern throughout cells (Fig. 3A). This
staining profile was similar to that observed previously for wt
HIVgpt CA (McDermott et al., 1996; Wang and Barklis, 1993;
Wang et al., 1993; Zhang and Barklis, 1997), and for the
MAGFP Gag protein of Muller et al. (2004), and was not
altered appreciably by the addition of phorbol esters (Fig. 3B).
Interestingly, AKT PH, which binds to 3′ PIs, and PLC PH,
which binds PI(4,5)P2 both targeted their respective Gag
proteins to the PM, as indicated by the strong cell surface
staining of the GFP-AKTPH-Gag (Fig. 3C) and GFP-PLCPH-
Gag proteins (Fig. 3D). For PKCCBD-GFP-Gag, proteinsFig. 3. Fluorescence localization of proteins in transfected cells. Fluorescence
localization of proteins in transfected cells. Cells on coverslips that were
transfected with the indicated constructs were either untreated (panels A–E) or
treated with 1 μM PMA (panels B, F). Subsequently, cells were processed for
microscopic analysis of GFP proteins as described in the Materials and methods
section, imaged on a Zeiss Axioplan fluorescence microscope, and photo-
graphed using Improvision OpenLab software. A 20-μm size bar for all panels is
provided at the bottom of the panel.accumulated in large aggregates, often adjacent to cell nuclei
(Fig. 3E), but this pattern was shifted somewhat to smaller
aggregates and more surface staining on PMA treatment
(Fig. 3F).
In an effort to quantitate our fluorescence staining observa-
tions, we calculated cell surface staining levels. To do so,
fluorescence levels corresponding to the outermost 20% of cell
radii were expressed as percentages of total cell fluorescence
signals (see Materials and methods) to give percentages of cell
surface staining. For HIVgpt-MAGFP, we calculated the cell
surface staining percentage to be 29±4%, presumably reflect-
ing the fact that wt PrGag proteins localize both to the PM and
to intracellular membrane and vesicle compartments (Dong et
al., 2005; Jouvenet et al., 2006; Lindwasser and Resh, 2004;
Nydegger et al., 2003, Ono and Freed, 2004). PMA treatment
did not alter this surface staining percentage (28±5%).
Relative to these levels, the PH replacement proteins demon-
strated higher surface staining, with percentages of 36±7% for
GFP-AKTPH-Gag and 39±6% for GFP-PLCPH-Gag. Not
surprisingly, surface staining levels were low (15±5%) for
PKCCBD-GFP-Gag, but increased slightly to 23±4% on PMA
treatment.
As another approach to the localization of Gag proteins
within cells, we resorted to electron microscopy (EM), relying
on the tendency of Gag protein aggregates to stain darkly in
negatively stained thin sections (Arvidson et al., 2003; Facke
et al., 1993; Hockley et al., 1988). For a control in these
studies, we used PR− but otherwise wt HIV-1 Gag expression
construct (HIVgpt PR−; McDermott et al., 1996; Wang and
Barklis, 1993; Wang et al., 1994; Zhang and Barklis, 1997). In
agreement with previous work (Arvidson et al., 2003), wt PR−
HIV-1 particles were observed budding and at cell surfaces
(Figs. 4A–C). In contrast, the GFP-AKTPH-Gag proteins
showed a variety of structures (Figs. 4D–F). Occasionally,
large vesicles containing black rimmed smaller vesicles and
darkly staining virus-sized spherical structures were observed
(Fig. 4D). However, virus-like budding structures, or VLPs
within budding structures (Figs. 4E, F) also were seen. Relative
to the structures assembled in GFP-AKTPH-Gag-transfected
cells, those formed by GFP-PLCPH-Gag (Figs. 4G–I) and
PKCCBD-GFP-Gag (Figs. 4J–L) were more consistent. In
particular, for GFP-PLCPH-Gag, particle assembly occurred at
the PM. This was indicated by the appearance of electron dense
nascent buds at the PM (Fig. 4G), as well as small (Fig. 4H)
and large (Fig. 4I) budding structures. For PKCCBD-GFP-Gag,
the picture was quite different. Rather than assembly at the PM,
these proteins associated in large (Figs. 4J, K) or small clusters
or aggresomes (Johnston et al., 1998). We did not observe any
obvious reduction in the numbers of aggresomes in PMA
treated PKCCBD-GFP-Gag-transfected cells (data not shown),
suggesting that the quantitative effects of phorbol esters on the
release (Fig. 2) and localization (Fig. 3) were not dramatic
enough to be scored by EM.
Despite the localization differences between the wt and
matrix replacement Gag proteins, it was of interest to assess
whether the proteins might cross paths within cells. We ex-
amined this by coexpression of wt HIV-1 Gag-β-galactosidase
Fig. 4. Electron microscopy of transfected cells. Electron microscopy of transfected cells. Cells were transfected with constructs expressing protease-minus but
otherwise wild type HIV Gag (wild type PR−; panels A–C), GFP-AKTPH-Gag (panels D–F), GFP-PLCPH-Gag (panels G–I), or PKCCBD-GFP-Gag (panels J–L).
At 3 days post-transfection, cells were fixed, post-fixed, dehydrated, embedded, sectioned, and stained for electron microscopy as described in the Materials and
methods. As illustrated, relatively homogeneous wild type PR− particles were observed at the surfaces of cells (A–C), while structures assembled by GFP-AKTPH-
Gag proteins were pleiomorphic and appeared as VLPs or darkly rimmed vesicles within intracellular vacuoles (D), particles released at the cell surface (E), or
preformed VLPs near the cell surface or within attached or sheared filopodia (F). In contrast, assembly of spherical or tubular GFP-PLCPH-Gag VLPs occurred
specifically at cell surfaces (G–I), and PKCCBD-GFP-Gag proteins assembled into large intracellular aggresomes (J–L).
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Gag proteins in cotransfected HEK 293 cells. As previously
observed (Wang et al., 1994), expression of HIV-1 Gag-β-gal
in the absence of any helper proteins resulted in very low
levels of Gag-β-gal release from cells, and treatment with
PMA or coexpression with murine leukemia virus (MuLV)
Gag proteins failed to increase levels of release. However,
cellular coexpression of HIV-1 Gag-β-gal and wt HIV-1 Gag
proteins caused the efficient assembly and release of β-gal-
positive (β-gal+) VLPs (data not shown), as described
previously (Wang et al., 1994). The Gag proteins with PH
domains also efficiently facilitated the efficient release of β-
gal+ VLPs, while PKCCBD-GFP-Gag proteins induced β-gal
release to a lower extent, and in a phorbol ester-dependent
fashion (data not shown). Altogether, these results demon-
strate that despite their different membrane-targeting signals,
wt and MA substitution proteins are able to associate with
each other within cells.Replication defects of chimeric Gag proteins
Since alternative MBDs were able to direct the release of
VLPs, albeit to different degrees, and with potentially different
morphologies, we next tested whether they were compatible
with virus replication. For these studies, we replaced the MA
domain in HIVgpt (Page et al., 1990; Wang and Barklis, 1993)
with MBDs, excluding GFP domains. The resulting constructs,
HIVgpt-AKTPH, HIVgpt-PLCPH, and HIVgpt-PKCCBD,
retained the wt HIV-1 MA-CA cleavage region and the MA
N-terminus, but bore the glycine-to-alanine mutation at gag
codon 2, to prevent Gag protein myristoylation (Bryant and
Ratner, 1990; Wang and Barklis, 1993; Wang et al., 1994). We
scored for replication in single cycle infections via cotransfec-
tion of HIVgpt-derived constructs with a Vesicular Stomatitis
virus glycoprotein (VSV-G) expression construct (pVSV-G)
into HEK 293 cells, collection of released virions for infection
of CD4+ HeLa (HiJ; Scholz et al., 2005; Wang and Barklis,
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pression. As illustrated in Fig. 5, while mock-infected HiJ cells
were killed in gpt selective media, numerous darkly staining
colonies derived from wt HIVgpt infected cells survived
selection. In our hands, with Gag-normalized input virus, our
GFP insertion construct HIVgpt-MAGFP (Fig. 1) proved to be
about 10% as infectious as wt (Fig. 5). This level of infection
was about 10-fold higher than that observed by Muller et al.
(2004), but those investigators used a slightly different MAGFP
construct, employed the wt HIV-1 Env protein, and scored
infection in an alternative fashion. In contrast to HIVgpt and
HIVgpt-MAGFP, our matrix replacement HIVgpt constructs
failed to demonstrate any infectivity (Fig. 5), and identical
results were observed when we pseudotyped the viruses with
either HIV-1 Env, or an amphotropic MuLV Env (data not
shown). We then verified that vRNAs transcribed by MA
substitution constructs could be encapsidated, reverse tran-
scribed, integrated and expressed in target cells. To do so,
constructs were cotransfected with pVSV-G plus a wt gpt-
minus HIV-1 Gag expression construct (HIV-Luc; Scholz et al.,
2005), and infectivities of released viruses were scored by
selection for gpt. In these studies, wt Gag proteins efficiently
fostered the transduction of HIVgpt-ADKPH, HIVgpt-PLCPH,
and HIVGPT-PKCCBD genomes to target cells (data not
shown), implying that the matrix replacement vRNAs did not
carry a cis-active defect for replication.
The lack of infectivity for HIVgpt-AKTPH, HIVgpt-PLCPH,
and HIVgpt-PKCCBD viruses did not appear to be a con-
sequence of impaired particle assembly and release, since the
constructs yielded detectable levels of PrGag and CA proteins in
pelleted media samples (Fig. 6, top panel, lanes E–H). Com-
pared with cellular Gag protein levels (Fig. 6, top panel, lanesFig. 5. Virus infectivity. Virus infectivity. Viruses were produced by mock transfecti
HIVgpt (WT), HIVgpt-MAGFP (MAGFP), HIVgpt-AKTPH (AKTPH), HIVgpt-PL
viruses, transfected cells were treated with 1 μM PMA as described in the Materia
containing media supernatants were collected, filtered through 0.45-μm sterile filters
into gpt selective media, and colonies expressing proviral gpt genes were grown forA–D), HIVgpt wt and HIVgpt-PLCPH showed similar VLP
release levels (Fig. 6, middle panel), HIVgpt-AKTPH showed
about a two-fold reduction in VLP release (Fig. 6, middle panel),
and HIVgpt-PKCCBD showed at least a ten-fold release
reduction (Fig. 6, middle panel) even in the presence of PMA.
However, these release reductions were comparatively small,
relative to the observed infectivity block of over a thousand-fold
(Fig. 5).
Despite the appearance of PrGag and CA bands for the matrix
substitution HIVgpt variants, several anomalies were evident. In
particular, HIVgpt-AKTPH and HIVgpt-PLCPH VLP prepara-
tions both showed immunoreactive bands of slightly slower
mobility than their respective predicted 57–58 kDa PrGag
proteins (Fig. 6, top panel, lanes F, G). Because the intensities of
these low mobility species varied from preparation to prepara-
tion, we hypothesized that they might represent variable post-
translational modification forms; but they were resistant to
endoglycosidase F, and were unreactive to anti-phosphotyro-
sine, anti-phosphothreonine, and anti-phosphoserine antibodies,
suggesting that they did not result from N-glycosidation or
phosphorylation (data not shown). In addition to these low
mobility species, some Gag processing differences were noted.
Although all of theMA replacement particle preparations looked
similar to wt with regard to their levels of partial processing
intermediates, PrGag percentages were increased, at the expense
of mature CA (Fig. 6, bottom panel). These processing
differences appeared relatively minor for HIVgpt-AKTPH, but
were clearly skewed for HIVgpt-PLCPH, where only a third
of the particle-associated Gag protein was in the mature form
(Fig. 6, bottom panel).
Because MA substitution viruses were functionally im-
paired, we decided to examine VLP morphologies of HIVgpton (mock) or cotransfection of 293T cells with a VSV-G expression vector plus
CPH (PLCPH) or HIVgpt-PKCCBD (PKCCBD). For production of PKCCBD
ls and methods to improve particle release. At 3 days post-transfection, virus-
and used to infect HiJ cells. Three days post-infection, HiJ cells were split 1:10
7–10 days prior to staining.
Fig. 6. Virus-like particle release and processing. Top panel. Virus-like particle
release and processing. Top panel. Cell lysate (A–D) and VLP (E–H) samples
were collected from cells transfected with wt HIVgpt (wt), HIVgpt-AKTPH
(AKTPH), HIVgpt-PLCPH (PLCPH) or HIVgpt-PKCCBD (PKCCBD), and
either untreated or treated with 1 μM PMA (+PMA). Gag proteins in samples
were fractionated by SDS-PAGE, and detected by immunoblotting using an anti-
HIVCA primary antibody. Size marker mobilities, as well as PrGag and CA
bands, are indicated. Middle panel. Virus-like particle assembly and release
levels, normalized to that of wt HIVgpt, were determined as described in Fig. 2,
including a myristoylation-minus HIVgpt construct (Myr− HIV) as a negative
control. Values derive from two (PKCCBD, Myr− HIV), three (PKCCBD), or
four (AKTPH, PKCCBD+PMA) independent experiments, with standard
deviations as shown. Bottom panel. PrGag processing levels for VLPs produced
from cells expressing wt HIVgpt (wt), AKTPH, PLCPH, and PKCCBD (in the
presence of PMA) were determined by densitometric quantitation of PrGag
(light gray), processing intermediates (medium gray), and CA bands (dark gray)
from immunoblots. Values represent percentages of the total virus-associated
Gag levels (plus standard deviations) and derive from three (PKCCBD+PMA),
four (AKTPH, PLCPH), or seven (wt) independent VLP preparations.
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PLCPH) by EM. To do so, pelleted particles from transfected
cell media samples were applied to EM grids, dried, stained and
imaged, as we have done previously (Scholz et al., 2005).Examination of 100 particles of each virus type showed that
they had comparable diameters (Fig. 7, lower right). We also
scored for the percentages of particles with roughly conical or
cylindrical cores, and found that wt and HIVgpt-AKTPH results
were similar (65%), while the percentage for HIVgpt-PLCPH
was slightly reduced (50%; Fig. 7, upper right). However, we
noted some differences that were difficult to quantitate. In
particular, HIVgpt-AKTPH cores occasionally appeared to have
abnormalities (Fig. 7, AKTPH, leftmost image), and frequently
stained poorly at the narrow cone ends (right two images).
HIVgpt-PLCPH cores seemed even more aberrant, and were
often short (PLCPH, leftmost two images) or poorly staining
(rightmost image) at narrow ends.
The above observations suggest that alternative MBDs
interfere with the formation of mature infectious virus cores. To
examine the replication defects of HIVgpt-AKTPH and
HIVgpt-PLCPH particles in more detail, viruses produced by
these constructs were subjected to additional assays: we ex-
cluded HIVgpt-PKCCBD from these analyses, due to difficul-
ties in obtaining sufficient material. For quantitation of vRNA
encapsidation, virus particle vRNA levels were determined by
RNAse protection, as we have done previously (Scholz et al.,
2005; Wang et al., 1993; Zhang and Barklis, 1997). However,
since we have demonstrated that HIV-1 MA is not needed for
efficient vRNA encapsidation (Wang et al., 1993), it was not
surprising that our PH HIVgpt variants incorporated 83%
(AKTPH) to 104% (PLCPH) wt amounts of vRNA into viruses.
Another parameter that conceivably could have affected in-
fectivity was the efficiency of VSV-G pseudotyping. We as-
sayed this via parallel immunoblotting of virus samples for
detection of Gag and VSV-G, but found that VSV-G-to-Gag
ratios either were not reduced (AKTPH) or only slightly re-
duced (PLCPH) relative to wt ratios. These observations were
consistent with our entry assay results. Here, we followed
previously reported methodology (Munk et al., 2002; Scholz
et al., 2005; see Materials and methods) to score for virus-
mediated β-lactamase Vpr (BlaM-Vpr) fusion protein delivery
to HiJ target cells. Although entry levels ranged between two-
thirds (PLCPH) and 170% (AKTPH) that of wt levels, these
differences were small compared to the infectivity block
(Fig. 5). Thus, the dominant defect of our MA substitution
variants does not appear to be virus core delivery to new cells.
While delivery of HIVgpt-AKTPH and HIVgpt-PLCPH
VLP cores to HiJ cells was not impaired appreciably, the
replicative capacities of the cores were compromised. One
indication of this defect was a reduction in the RT levels asso-
ciated with matrix replacement VLPs. Indeed, Gag-normalized
RT levels for HIVgpt-AKTPH particles were reduced two-fold
from wt, while activities for HIVgpt-PLCPH were only 15% of
wt levels. These RT defects were more evident when reverse
transcription products were monitored in infected cells. For
these assays, one long terminal repeat (1-LTR) RT byproducts
(Butler et al., 2001) in infected cells were measured after PCR
amplification as described in the Materials and methods.
Importantly, 1-LTR products were detected readily for HIVgpt
wt, but were undetectable with the MBD variants, indicating
that their virus cores failed to complete RT steps in target cells.
Fig. 7. Electron microscopy of virus-like particles. Electron microscopy of virus-like particles. Wild type (wt; black bars) HIVgpt, HIVgpt-AKTPH (AKTPH; gray
bars), and HIVgpt-PLCPH (PLCPH; white bars) virus-like particles (VLPs) were lifted onto EM grids, stained, dried, and imaged by electron microscopy (EM).
Micrographs show VLPs with central, roughly conical cores, and the white size bar in the upper right panel corresponds to 100 nm for all pictures. The graphs on the
right shows the average VLP diameters, and the percentages of VLPs with discernable, roughly conical or cylindrical cores: each value was derived from 100 separate
VLP images.
Fig. 8. Analysis of viral reverse transcriptase proteins. Analysis of viral reverse
transcriptase proteins. VLP samples were collected from cells transfected with
wt HIVgpt (A), HIVgpt-AKTPH (B), HIVgpt-PLCPH (C), or HIVgpt-
PKCCBD (D), and either untreated or treated with 1 μM PMA (+PMA).
Proteins in Gag-normalized samples were fractionated by SDS-PAGE, and
detected by immunoblotting using an anti-HIVRT primary antibody. Size
marker mobilities, as well as 66 kDa RT-RH and 51 kDa RT bands, are
indicated. Note that no other bands were detected with the anti-RT antibody, but
that similarly sized bands for the MBD variants (B–D) were detected in parallel
immunoblots with an anti-HIVPR antibody.
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RT proteins in HIVgpt wt, HIVgpt-AKTPH, HIVgpt-PLCPH,
and HIVgpt-PKCCBD VLPs. Surprisingly, whereas wt VLPs
showed the expected 66 kDa RT-RNAse H (RT-RH) and
51 kDa RT species, our three MBD variant VLPs each revealed
a single immunoreactive band at a mobility of about 75 kDa
(Fig. 8). Because species with this mobility also were detected
with an anti-PR antibody (data not shown), our data indicate
that these bands represent PR-RT-RH processing intermediates
(Pettit et al., 2004, 2005). These results suggest that MA
replacements exert an influence on PrGagPol cleavages that
occur after Gag and Pol are separated, and are consistent with
reduced RT and PrGag processing levels in our chimeric
viruses.
Discussion
The HIV-1 matrix domain targets PrGag proteins to as-
sembly sites on cellular membranes, and is required for incor-
poration of full-length HIV-1 Env proteins into virus particles
(Bryant and Ratner, 1990; Davis et al., 2006; Dorfman et al.,
1994; Freed and Martin, 1995, 1996; Mammano et al., 1995;
Ono and Freed, 1999, 2004; Ono et al., 1997, 2000a,b; Pal et al.,
1990; Wang and Barklis, 1993; Wang et al., 1993; Wyma et al.,
2000; Yu et al., 1992; Zhou et al., 1994). However, PrGag
proteins with MA deletions that retain myristoylation signals
and MA/CA cleavage sites are able to direct the assembly of
infectious virions, provided that the particles are pseudotyped
with heterologous Env proteins or C-terminally truncated HIV-1
Env proteins (Reil et al., 1998; Wang et al., 1993). These resultsmay suggest that both full-length and MA-deleted, myristoy-
lated HIV-1 PrGag proteins are targeted to membrane sites
that are permissive for the assembly of infectious virions. Al-
ternatively, virus assembly simply may require the delivery of
the C-terminal Gag domains to a membrane surface, with few
additional requirements.
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relatively tolerant of the MBD used to foster membrane
association. Specifically, the AKT PH, which binds 3′ PI lipids
(Haugh et al., 2000; Hurley and Meyer, 2001; Lemmon, 2003;
Marshall et al., 2001), and the PLC PH, which binds PI(4,5)P2
(Hurley andMeyer, 2001; Lemmon, 2003; Stauffer et al., 1998),
both mediated the assembly and release of VLPs (Figs. 2 and 6).
Efficient VLP release occurred in the absence of PI 3-kinase and
PI(4)P 5-kinase activation, implying that basal levels of PM PI
(3,4,5)P3 and PI(4,5)P2 were sufficient for cell surface
localization. In contrast to the two PH domains, the cysteine-
rich membrane-binding domain of PKC (PKCCBD; Colon-
Gonzalez and Kazanietz, 2006; Edwards and Newton, 1997;
Hurley and Meyer, 2001; Oancea and Meyer, 1998; Oancea
et al., 1998) directed Gag protein accumulation into large
aggresomes (Johnston et al., 1998; Figs. 3 and 4). However,
consistent with the ability of the PKCCPD to bind DAG and
phorbol esters (Colon-Gonzalez and Kazanietz, 2006; Edwards
and Newton, 1997; Hurley and Meyer, 2001; Oancea and
Meyer, 1998; Oancea et al., 1998), cell treatment with PMA or
PDB boosted VLP release from cells (Figs. 2 and 6). Despite
their different cellular itineraries and membrane-binding
mechanisms, all of our MA substitution Gag proteins were
able to facilitate the release of wt HIV-1 Gag-β-gal proteins
from cotransfected cells, which demonstrate that there is some
overlap in the pathway taken by Gag-β-gal proteins with wt MA
domains, and the assembly and release routes taken by the
matrix replacement proteins.
Although our alternative MBDs sufficed for VLP assembly
and release, they failed to support virus replication (Fig. 5).
For the PH variants, vRNA encapsidation, VSV-G pseudo-
typing, and entry all occurred at wt or slightly diminished
levels. However, reverse transcription in infected cells was
greatly impaired, and viruses showed reduced RT activities,
moderate to severe PrGag processing defects (Fig. 6), and the
appearance of altered mature cores (Fig. 7). Notably, VLPs
assembled by all three MA replacements carried PR-RT-RH
proteins, and did not show the normal 66 kDa RT-RH and
51 kDa RT products (Fig. 8). This finding is consistent with
the observed RT and PrGag processing detects of MBD
variant viruses. However, our results imply that MBDs
influence PrGagPol processing steps that occur after Pol
domains are freed from their co-translated partners. Formally,
MBDs could interfere with later PrGagPol cleavages via a
direct interaction with PR domains. Alternatively, they may
exert their effects as a consequence of their specific membrane
assembly sites, or through flexibility constraints imposed on
the viral proteins.
Previous reports have demonstrated that while the globular
head of HIV-1 MA can exert a negative effect on virus assembly
in some cellular contexts (Hatziioannou et al., 2005; Hubner
and Chen, 2006; Perez-Caballero et al., 2004), large sequence
insertions into MA can be accommodated for the purposes of
VLP assembly and release (Liao et al., 2004; Muller et al., 2004;
Wang et al., 2000). Moreover, matrix domain swapping studies
have revealed that some chimeric retrovirus PrGag proteins
efficiently assemble virions that can be infectious (Chen et al.,2001; Reed et al., 2002).We have extended these studies by
showing that the HIV-1 assembly machinery is flexible with
regard to its means of membrane association, but that alternative
MBDs directly or indirectly may interfere with the elaboration
of infectious virus cores.
Materials and methods
Recombinant DNA constructs
Wild type (wt) versions of the HIV-1 gag gene, expressed in
the presence of pol gene products were produced from the
previously described HIVgpt construct (Page et al., 1990; Wang
and Barklis, 1993; Wang et al., 1993). The myristoylation-
minus (Myr− HIV) and protease-minus (PR−; HIVgpt2498T)
variants of HIVgpt also have been described before (McDer-
mott et al., 1996; Wang and Barklis, 1993; Wang et al., 1994;
Zhang and Barklis, 1997). HIVgpt-MAGFP, encodes a Gag-
GFP fusion protein similar to that reported by Muller et al.
(2004), in which the green fluorescent protein (GFP) open
reading frame (orf) has been inserted near the C-terminus of the
gagmatrix domain. In HIVgpt-MAGFP, the backbone construct
is HIVgpt (Page et al., 1990; Wang and Barklis, 1993; Wang
et al., 1993), and the source of the GFP orf was pEGFP-c1
(Clontech). The 5′ juncture sequence is GCT GCG CTA GCG
CTA CCG GTC GCC ACC ATG, the first codon corresponds to
HIV HXB2 gag codon 120, while the last codon is the first GFP
codon. The 3′ juncture sequence is AAG TCC GGA CTC AGA
TCC GCT GAC, where the first codon corresponds to the final
coding codon of wt GFP, and the last codon is gag codon 121.
Alternative membrane-binding domain (MBD) constructs
were derived from pEGFPc1-AKTPH, pEGFPc1-PLCδPH, and
GFP-pcDNA3-PKCγCys1ACys1B, which all were kindly
provided by Tobias Meyer (Haugh et al., 2000; Hurley and
Meyer, 2001; Marshall et al., 2001; Oancea and Meyer, 1998;
Oancea et al., 1998; Stauffer et al., 1998). For GFP-AKTPH-
Gag and GFP-PLCPH-Gag, the MA-truncated HXB2 gag orf
was inserted C-terminal to the different pleckstrin homology
(PH) domains, yielding constructs in which the pEGFPc1
cytomegalovirus (CMV) promoter drives expression of GFP-
PH-Gag fusion proteins. The PH-gag juncture sequences for
GFP-AKTPH-Gag and GFP-PLCPH-Gag are respectively CTG
GGC CCA ACG AAT TCA TCT AGA GCT, and AAG GAG
CTC GGG ATATCTAGA GCT, where the final codon in each
sequence corresponds to gag codon 120. For PKCCBD-GFP-
Gag, the pcDNA3 (Invitrogen) CMV promoter drives expres-
sion of a fusion composed of PKC cysteine-rich membrane-
binding domain (CBD), GFP, and the MA-truncated HIV gag
orf: the GFP-gag juncture sequence is CTG TAC ACC GCG
GGATCC TCTAGA GCT, where the final codon is gag codon
120. Note that the HIV sequences in these constructs extend to
the BclI site at HXBC2 nt 2432, but that PR activity is killed via
fusion to a translation termination codon in an XbaI site, with
juncture sequences of TAT GAT CTC TAG A.
To create the MA replacement constructs HIVgpt-AKTPH,
HIVgpt-PLCPH, and HIVgpt-PKCCBD in the HIVgpt (Page
et al., 1990; Wang and Barklis, 1993; Wang et al., 1993)
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cine-to-alanine HIVgpt mutant plasmid (Wang and Barklis,
1993; Wang et al., 1994) was used as a parent. These constructs
harbor alternative MBDs between gag codons 15 and 120. The
N-terminal and C-terminal juncture sequences, with codons
15 and 120 italicized are as follows: AKTPH and PLCPH
N-junctures, CGA TGG GGA TCC; AKTPH and PLCPH
C-junctures, TCT AGA GCT; PKCCBD N-juncture, CGATAC
ATG GGG GCC CGG TAC CTT; PKCCBD C-juncture, CGG
TAC CAT GCC GCG GCC GGATCC TCT AGA GCT. Other
constructs used in these studies have been reported previously.
They include the following: BlaM-Vpr (Munk et al., 2002;
Scholz et al., 2005); the MuLV gag expression construct,
pXMGPE (Hansen and Barklis, 1995; McDermott et al., 2000);
the HIV Gag-β-galactosidase expression construct, HIVGBG
(Wang et al., 1994); pBluescribeHIV831-680 (Wang et al.,
1993; Zhang and Barklis, 1997), for RNAse protection probe
production; and the glycoprotein expression constructs pVSV-G
(Scholz et al., 2005), SV-A-MLVenv (Wang and Barklis, 1993;
Wang et al., 1993), and SV-A-MLVenv (Wang and Barklis,
1993; Wang et al., 1993).
Cells and viruses
Human embryonic kidney (HEK) 293T (Scholz et al., 2005)
and HiJ (Scholz et al., 2005; Wang and Barklis, 1993; Wang
et al., 1993) HeLa cells expressing human CD4 were grown at
37 °C in 5% CO2 in culture medium composed of Dulbecco's
modified Eagle medium (DMEM) supplemented with 10% fetal
calf serum, penicillin, streptomycin, and 10 mM HEPES (pH
7.4). For transfections, 10-cm dishes of 293T cells were trans-
fected by the calcium phosphate method (Scholz et al., 2005;
Wang and Barklis, 1993; Wang et al., 1993). For Gag analysis,
24 μg of plasmid DNAs (Fig. 1) was used; for infection assays,
16 μg HIV-derived DNAs was cotransfected with 8 μg envelope
protein expression plasmids; for entry assays, transfections
employed 12 μg of HIV-derived DNAs, plus 6 μg of pVSV-G
expression plasmid (Scholz et al., 2005), plus 6 μg of BlaM-Vpr
DNA (Munk et al., 2002; Scholz et al., 2005); while for Gag-β-
galactosidase (Gag-β-gal) experiments, 16 μg of Gag expres-
sion plasmids was cotransfected with 8 μg of HIVGBG (Wang
et al., 1994). Routinely, cell and virus samples were collected
3 days post-transfection. In some cases, the effects of phorbol
esters were tested by treatment with a 1:1000 dilution of 1 mM
phorbol myristate acetate (PMA; Sigma) or phorbol dibutyrate
(PDB) at 24 h and again at 6 h prior to sample collection. Cell
pellets were collected and washed in phosphate-buffered saline
(PBS; 9.5 mM sodium potassium phosphate [pH 7.4], 137 mM
NaCl, 2.7 mM KCl). Virus-containing media were filtered
through 0.45-μm-pore filters (Gelman) and concentrated by
centrifugation through 20% sucrose in PBS cushions (2 h at
82,500 ×g [25,000 rpm in a Beckman SW28 rotor, 4 ml cu-
shions] or 45 min at 197,000 ×g [40,000 rpm, SW41 rotor, 2-ml
cushions]). Virus pellets were resuspended in 0.1 ml PBS per
cell plate and stored in aliquots at −80 °C.
To test virus infectivities, confluent 10-cm dishes of HiJ cells
were split 1:40 onto 35-mm dishes the day before infections.For infections, cells were incubated at 37 °C for 72 h in the
presence of filtered virus in a total volume of 2 ml culture
media. Subsequently, cells were transferred to 10-cm dishes
and fed with selection media containing 9.35 ml of culture
media, 0.65 ml of gpt supplement solution (3.85 mg/ml
xanthine, 0.046 mg/ml hypoxanthine, 0.062 mg/ml thymidine,
0.154 mg/ml glycine, 2.308 mg/ml glutamine), and 15 μl of
mycophenolic acid (Gibco) per plate. Cells were selected for
10–14 days, with selection media changed at 3–4-day
intervals. After selection, gpt-positive colonies were stained
with 0.5% methylene blue in 50% methanol, gently rinsed in
water and dried prior to colony counting. Infectivity was
calculated as follows: Virus titer= (colonies)(virus dilution
factor)(cell split ratio) / (cell proliferation between infection
and selection). Results were normalized to input virus Gag
protein levels.
Protein analysis
For protein analysis, cell samples (20% of pellets from each
10-cm plate) were suspended in IPB (20 mM Tris–HCl [pH
7.5], 150 mM NaCl, 1 mM ethylenediamine tetraacetic acid
[EDTA], 0.1% sodium dodecyl sulfate [SDS], 0.5% sodium
deoxylate, 1.0% Triton X-100, 0.02% sodium azide), incubated
on ice for 5 min, vortexed, and subjected to centrifugation
13,000 ×g for 15 min at 4 °C. Soluble material was collected,
mixed with 1 volume of 2× sample buffer (12.5 mM Tris–HCl
[pH 6.8], 2% SDS, 20% glycerol, 0.25% bromophenol blue)
and 0.1 volume of β-mercaptoethanol (β-Me). For virus sam-
ples, 40 μl aliquots of resuspended virus pellets were mixed
with 1 volume of 2× sample buffer and 0.1 volume of β-Me.
Cell and virus samples were heated to 95 °C for 3 to 5 min, and
subjected to SDS-polyacrylamide electrophoresis (SDS-PAGE).
After SDS-PAGE fractionation, proteins were electroblotted,
and immunoblotted following previously described methods
(Hansen and Barklis, 1995; Jones et al., 1990; McDermott et al.,
1996, 2000; Scholz et al., 2005; Wang and Barklis, 1993; Wang
et al., 1993, 1994; Zhang and Barklis, 1997). The antibody used
for detection of HIV-1 CA was Hy183 (kindly provided by
Bruce Chesebro), used at 1:15 dilution from the hybridoma
culture medium. Antibodies obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH were the HIV-1 RT monoclonal antibody
(MAb21) from Dr. Stephen Hughes, used at 1:300; and HIV-1
protease antisera from HIVSF2 from BioMolecular Technology,
used at 1:1000. Other primary antibodies were anti-VSV-G
(Roche), used at 1:400; and anti-GFP (Invitrogen #A11121),
used at 1:1000. In all cases, the secondary antibody was an anti-
mouse IgG alkaline phosphatase-conjugated secondary anti-
body (Promega) that was used at 1:15,000. Color reactions for
visualization of antibody-bound bands employed nitroblue
tetrazolium plus 5-bromo-4-chloro-3-indolyl phosphate in AP
buffer (100 mM Tris–hydrochloride [pH 9.5], 100 mM NaCl,
5 mM MgCl2). For quantitation, immunoblots were air-dried
and scanned using an Epson G810A scanner. Band intensities of
scanned TIFF images were quantitated using NIH Image 1.61
software.
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For RNA analysis, viral RNA samples were obtained from
virus pellets that were resuspended in 200 μl PBS, and sup-
plemented with 2 μl of 10% SDS plus1 μl of 10 mg/ml carrier
E. coli tRNA (Roche). Samples were extracted twice with
200 μl of 1:1 phenol:chloroform, extracted twice with 200 μl
chloroform, ethanol-precipitated, dried, and resuspended in
50 μl of TE buffer (10 mM Tris [pH 7.8], 0.1 mM EDTA). To
isolate cellular RNA samples, 10-cm dishes of cell monolayers
were washed, suspended in 1 ml of GTC mix (4 M guanidium
thiocyanate, 25 mM sodium citrate [pH 7.0], 0.5% sarkosyl,
0.1 M β-Me), layered onto CsCl/EDTA (6.2 M CsCl, 0.1 M
EDTA [pH 7.0]) cushions, and centrifuged at 115,000 ×g
(35,000 rpm in a Beckman SW50.1 rotor) for 18 h at 15 °C.
After centrifugation, supernatants were removed, and pellets
were resuspended in 400 μl TE, phenol–chloroform-extracted
twice, chloroform-extracted once, ethanol-precipitated, dried,
and resuspended in 100 μl TE. Samples were quantitated by
measuring UV absorbance at 260 nm in a Beckman DU-64
spectrophotometer, assuming an extinction coefficient of 1
optical density (O.D.) unit per 40 μg/ml RNA at a pathlength of
1 cm.
Probes for RNAse detection were made by incubation of 1 μg
of EcoRI-linearized template plasmid (pBluescribeHIV831-
680; Wang et al., 1993; Zhang and Barklis, 1997) with
transcription buffer (40 mM Tris [pH 7.4], 10 mM DTT,
6 mM MgCl2, 0.8 mM spermidine), 100 μCi of [α-
32P]rGTP,
0.5 mM each of rATP, rCTP, and rUTP, 1 μl of RNasin
(Promega), 1 mM dithiothreotol [DTT], and 20 U of T3 poly-
merase (Promega) at 37 °C for 1 h. Probes then were ethanol-
precipitated, dried, resuspended, separated on 5% sequencing
gels (Wang et al., 1993; Zhang and Barklis, 1997), eluted, and
reprecipitated prior to use (Wang et al., 1993; Zhang and Barklis,
1997). For RNAse protections, RNA-normalized cell samples or
Gag-normalized viral samples were precipitated with 10 μg of
tRNA. Pellets were resuspended in 30 μl of 80% formamide,
400 mM NaCl, 40 mM piperazine-N,N-bis(2-ethanesulfonic
acid) (PIPES, pH 6.4), mixed with probe, incubated at 75–85 °C
for 5 min, and then incubated at 30 °C overnight. Overnight
incubation samples were supplemented with 350 μl RNAse
treatment buffer (300 mM NaCl, 10 mM Tris [pH 7.5], 5 mM
EDTA, 40 μg/ml RNAse A [Rochel, 2 μg/ml RNAse T1
[Roche]) and incubated at 30 °C for 30 min, followed by the
addition of 2.5 μl of 20 mg/ml proteinase K (Boehringer) plus
20 μl of 10% SDS and further incubation at 37 °C for 15 min.
Samples subsequently were phenol–chloroform extracted,
chloroform extracted, ethanol-precipitated, dried, fractionated
on 6% acrylamide sequencing gels, and autoradiographed. Viral
genomic RNA bands on autoradiographs were scanned using an
Epson G810A scanner, and quantitated using NIH Image 1.61
software.
For detection of one long terminal repeat (1-LTR) circles in
infected cells, HiJ cells were split 1:40 onto 35-mm plates 1 day
prior to infection. Cells on plates were infected 72 h in a total
volume of 2 ml virus plus media, and then washed, collected in
500 μl PBS, pelleted, suspended in 200 μl PCR lysis buffer(10 mM Tris [pH 8.3], 50 mM KCl, 1.5 mM MgCl2, 0.01%
gelatin, 0.45% NP-40, 0.45% Tween-20, 100 μg/ml proteinase
K [Sigma]), incubated at 55 °C 2–20 h, heated to 100 °C for
10 min, and then stored at −80 °C. One and two LTR circles in
0–4 μl lysate samples were amplified by polymerase chain
reaction (PCR). Reactions employed Taq DNA polymerase
(New England Biolabs; NEB) plus primers corresponding to
HIV-1 HXB2 nucleotides 9038–9058 and 1221–1202, and
were performed for 35–45 cycles with cycle times of 95 °C
1 min, 55 °C 1 min, 72 °C 2.5 min. Aliquots of PCR reactions
were fractionated electrophoretically on horizontal 0.9%
agarose–TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA,
pH 8.2) gels in parallel with Lambda HindIII and PhiX HaeIII
DNA size standards, and stained with ethidium bromide.
Stained DNA bands were imaged under UV light using a Kodak
EDAS 290 Gel Photo system, and 1-LTR circle products were
quantitated as a marker for reverse transcription in infected cells
(Butler et al., 2001) using NIH Image 1.61 software.
Enzyme assays
Exogenous reverse transcriptase (RT) assays were performed
with poly(A) and oligo(dT) templates and primers and
detergent-disrupted virions (Scholz et al., 2005; Wang and
Barklis, 1993). Gag-normalized virus samples in PBS were
incubated at 37 °C for 2 h in RT assay cocktail (50 mM Tris [pH
8.3], 20 mM dithiothreitol [DTT], 0.6 mM MnCl2, 60 mM
NaCl, 0.05% NP-40, 2.5 μg/ml of oligo(dT) [Pharmacia],
10 μg/ml of poly(A) [Pharmacia], 10 μM dTTP [1 Ci/mM
{α-32P}dTTP]). Dilutions of avian myeloblastosis virus (AMV)
RT (Roche) were run in parallel as controls. Following incu-
bations, samples were precipitated by addition of 0.1 volume of
100% trichloroacetic acid (TCA) and incubated overnight at
4 °C. TCA precipitates were pelleted by centrifugation for
10 min at 13,600 ×g at 4 °C, washed five times with 10% TCA,
and quantitated in a scintillation counter (Beckman).
For β-galactosidase (β-gal) assays, cells and viruses were
collected from 10-cm plates and processed as described above.
Sample aliquots (half of each virus sample, or 10% of each cell
sample) in 150 μl PBS were mixed with 1.5 μl of 10% SDS and
600 μl of PM2 buffer (33 mM NaH2PO4, 66 mM Na2HPO4,
0.1 mM MnCl2, 2 mM MgSO4, 40 mM β-Me), and vortexed.
Reactions were initiated by the addition of 150 μl of 4 mg/ml o-
nitrophenyl β-D-galactopyranoside (ONPG; Sigma) in PM2;
incubations proceeded at 37 °C until color changes were
observed; reactions were quenched with 375 μl of 1 M Na2CO3;
and β-gal activities were calculated from 420 nm absorbance
readings as described previously (Jones et al., 1990; Wang et al.,
1994).
Enzymatic entry assays followed previously reported proto-
cols and scored for β-lactamase activity delivered to target cells
by BlaM-Vpr fusion proteins (Munk et al., 2002; Scholz et al.,
2005). Confluent 10-cm dishes of HiJ cells were split 1:40 onto
35-mm dishes the day before infections. Cells were infected
overnight at 37 °C in a total volume of 2 ml cell culture media.
After infections, supernatants were removed, cells were washed
with Hank's balanced salt solution (HBSS) without calcium or
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solution (2 μM CCF2/AM; Invitrogen) at 26 °C and in 5% CO2
for 4 h. Loading solution then was removed, cells were washed
in HBSS, trypsinized, pelleted, fixed in 1% paraformaldehyde
in PBS for 20 min, pelleted, washed in HBSS, pelleted, and
resuspended in 500 μl HBSS. For analysis, fluorescence
profiles of infected cells were monitored on a Becton-Dickinson
Turbo Vantage flow cytometer to quantitate cleaved product as
blue fluorescence and uncleaved substrate as green fluorescence
signals. Cells were gated on the infected, unstained control
samples, and the percentages of cells positive for product were
normalized to Gag protein levels in input virus samples.
Microscopy
To examine GFP-positive virus particles, 20 μl aliquots of
suspended virus particle preparations were deposited on
microscope slides, covered with 22-mm×22-mm coverslips
(Fisher), viewed on a Zeiss Axioplan fluorescence microscope,
and imaged using Improvision OpenLab software. For
fluorescence microscopy of transfected cells, 22-mm×22-mm
coverslips in 6 well dishes were pretreated with 0.7% porcine
gelatin (Sigma) at 4 °C for 30 min, after which gelatin was
replaced with media. Transfected cells were split 1:40 or 1:80
from 10-cm plates onto coverslips 1 day post-transfection, in-
cubated for another 2 days, and then either mounted for GFP
fluorescence or processed for immunofluorescence and then
mounted. For GFP fluorescence, cells were washed once in
PBS, fixed in 4% paraformaldehyde (Sigma) in PBS at room
temperature for 1 h, washed in PBS, and mounted on slides
(Fisher) in Fluoro-G mounting medium (Southern Biotech). For
immunofluorescence, cells were fixed and washed as above,
and then permeabilized in 0.2% Triton X-100 in PBS at room
temperature for 10 min, washed once, and incubated in culture
medium for 10 min. Subsequently, anti-HIV-1 CA primary
antibody (Hy183, from Bruce Chesebro) in culture medium or
medium alone for negative controls was added, and cells were
incubated at 37 °C for 1 h, rocking every 15 min. After primary
antibody incubations, coverslips were washed three times in
culture medium, then secondary antibody (anti-mouse Alexa-
Fluor 594; Invitrogen) diluted 1:500 in media was added, and
the samples were incubated at 37 °C for 30 min, rocking once at
15 min. Following incubations, the cells were washed twice in
culture medium and three times in PBS, followed by mounting
onto microscope slides in Fluoro-G mounting medium. Samples
were viewed on a Zeiss Axioplan fluorescence microscope, and
photographed using Improvision OpenLab software. For quan-
titation of cell surface staining, rectangular sections from cell
centers to cell edges taken from 10 cells per sample were cut and
analyzed. To do so, brightness intensity signals ([number of
pixels]× [pixel brightness –− background brightness]) from the
outermost 20% of sampled areas were divided by brightness
intensity signals from the entire sample areas. These ratios,
multiplied by 100 were designated as percentages of cell surface
staining.
Electron microscopy (EM) of negatively stained virus
particles was performed as described by Scholz et al. (2005).Concentrated virus particle samples were lifted for 2 min onto
carbon-coated UV-treated EM grids, rinsed for 15 s in water,
stained for 1 min in filtered 1.3% uranyl acetate, wicked, and
dried. EM images were collected on a Philips CM120/Biotwin
TEM equipped with a Gatan 794 multiscan charge-coupled
device (CCD) camera. Virus particle diameters were determined
with the aid of Gatan digital micrograph software, and particles
were scored as having conical or cylindrical cores if projection
images showed negatively stained triangular, rectangular, or
trapezoidal structures. For EM of cells, transfected cells were
fixed, post-fixed, prestained, dehydrated, infiltrated, embedded,
sectioned and stained as described by Arvidson et al. (2003).
EM was performed on a Philips CM120/Biotwin, and 1024
pixel×1024 pixel images were collected electronically on a
Gatan 794 multiscan CCD camera.
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